The Company resolved to issue 4,989 stock options (share acquisition rights) free of charge to 47 of its executive officers and employees. If all are exercised, 498,900 common shares will be delivered, resulting in maximum dilution of 0.79%.
Issuance of Stock Options (Share Acquisition Rights) (株式会社ステムリム Series 19 Share Acquisition Rights (A))
4,989 share acquisition rights, representing 498,900 underlying common shares (100 shares per right)
The lower thin line represents the existing number of shares to which these shares will be added.
Free of charge
Maximum 0.79% (based on 62,681,200 issued shares as of 9 September 2026)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Stock Options (Share Acquisition Rights) (株式会社ステムリム Series 19 Share Acquisition Rights (A)) |
| Number of shares to be issued or disposed of | 4,989 share acquisition rights, representing 498,900 underlying common shares (100 shares per right) |
| Issue price and disposal price | No consideration per share acquisition right |
| Total issue value | Free of charge |
| Amount of funds to be raised | Total amount paid in: ¥0; estimated net proceeds: ¥0 |
| Intended allottee | 47 of the Company's executive officers and employees: 4,989 rights |
| Intended allottee's holding policy | The transfer of the share acquisition rights requires approval from the Company's Board of Directors. |
| Dilution Rate | Maximum 0.79% (based on 62,681,200 issued shares as of 9 September 2026) |
| Total number of issued shares | 62,681,200 shares → Not disclosed |
| Basis for determining the amount to be paid | The exercise price is the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the allotment date multiplied by 1.025, or the closing price on the most recent preceding trading day if no trade is concluded. This represents a 2.5% premium to the closing price. |
| Exercise price | Closing price on the allotment date × 1.025 (fractions of less than ¥1 rounded up). Adjusted for share splits or consolidations, the issuance of new shares or disposal of treasury shares at a price below market value, mergers and other events. The lower limit of the adjustment is Not disclosed. |
| Exercise period | From 11 September 2028 to 9 September 2036 |
| Number of Stock Acquisition Rights | Total issued: 4,989 rights. Unexercised balance: Not disclosed. |
| Reason for acquisition without consideration | If a merger in which the Company is the disappearing company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, is approved at a shareholders meeting. If a holder of the share acquisition rights no longer meets the exercise conditions and can no longer exercise the rights, or waives the rights. The Company may cancel the share acquisition rights it holds at any time free of charge. |
| Categories and Number of Persons Covered | 47 of the Company's executive officers and employees: 4,989 rights |
| Procedures under the Corporate Code of Conduct | The issuance was resolved by the Board of Directors at its meeting held on 9 September 2026, based on a resolution of the annual shareholders meeting held on 22 October 2025. Whether an independent third-party opinion was obtained is Not disclosed. |
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
To increase motivation and morale to contribute to advances in research and development, thereby contributing to higher corporate value, and to secure outstanding talent.